Skip to main content

Table 4 Prognosis of the clusters identified in the training and validation sets

From: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

Cohort   Risk cluster P valuea
   Total Low Medium High  
Training set
   Stockholm n 159 49 51 59  
  5-year eventb 38 (24%) 2 (4.2%) 7 (14%) 29 (49%) <10-7
Treated with adjuvant therapy
   Stockholm tamoxifen only N c 104 38 33 33  
  5-year event 22 (21%) 0 (0%) 6 (18%) 16 (48%) <10-6
   Uppsala node-positive n 76 14 27 35  
  5-year event 33 (43%) 2 (14%) 10 (37%) 21 (60%) 0.002
Untreated with adjuvant therapy
   Stockholm n c 33 7 10 16  
  5-year event 11 1 (14%) 0 (0%) 11 (69%) 0.002
   Uppsala node-negative n 135 51 55 29  
  5-year event 17 (12%) 3 (5.8%) 7 (13%) 7 (24%) 0.02
   Van't veer n 78d 19 33 25  
  5-year event 33 2 (17%) 18 (53%) 13 (55%) 0.01
  1. aP value for trend test.
  2. bDistant metastases or death within 5 years.
  3. cSubset of the Stockholm cohort: 82 patients with tamoxifen 2–5 years, eight patients with tamoxifen <2 years, nine patients with tamoxifen in sequence with megesterolacetat, and five patients with tamoxifen and goserelin.
  4. dOne patient was removed because of missing data. The 5-year event was distant metastases within 5 years.